GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nexalin Technology Inc (NAS:NXL) » Definitions » ROA %

Nexalin Technology (Nexalin Technology) ROA % : -128.80% (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Nexalin Technology ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Nexalin Technology's annualized Net Income for the quarter that ended in Mar. 2024 was $-4.16 Mil. Nexalin Technology's average Total Assets over the quarter that ended in Mar. 2024 was $3.23 Mil. Therefore, Nexalin Technology's annualized ROA % for the quarter that ended in Mar. 2024 was -128.80%.

The historical rank and industry rank for Nexalin Technology's ROA % or its related term are showing as below:

NXL' s ROA % Range Over the Past 10 Years
Min: -2883.9   Med: -739.04   Max: -41.49
Current: -112.26

During the past 4 years, Nexalin Technology's highest ROA % was -41.49%. The lowest was -2883.90%. And the median was -739.04%.

NXL's ROA % is ranked worse than
92.12% of 863 companies
in the Medical Devices & Instruments industry
Industry Median: -2.04 vs NXL: -112.26

Nexalin Technology ROA % Historical Data

The historical data trend for Nexalin Technology's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nexalin Technology ROA % Chart

Nexalin Technology Annual Data
Trend Dec20 Dec21 Dec22 Dec23
ROA %
-2,883.90 -1,394.04 -41.49 -84.04

Nexalin Technology Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -44.78 -59.21 -191.22 -77.46 -128.80

Competitive Comparison of Nexalin Technology's ROA %

For the Medical Devices subindustry, Nexalin Technology's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nexalin Technology's ROA % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Nexalin Technology's ROA % distribution charts can be found below:

* The bar in red indicates where Nexalin Technology's ROA % falls into.



Nexalin Technology ROA % Calculation

Nexalin Technology's annualized ROA % for the fiscal year that ended in Dec. 2023 is calculated as:

ROA %=Net Income (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=-4.649/( (7.432+3.632)/ 2 )
=-4.649/5.532
=-84.04 %

Nexalin Technology's annualized ROA % for the quarter that ended in Mar. 2024 is calculated as:

ROA %=Net Income (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=-4.164/( (3.632+2.834)/ 2 )
=-4.164/3.233
=-128.80 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2024) net income data. ROA % is displayed in the 30-year financial page.


Nexalin Technology  (NAS:NXL) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Mar. 2024 )
=Net Income/Total Assets
=-4.164/3.233
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-4.164 / 0.316)*(0.316 / 3.233)
=Net Margin %*Asset Turnover
=-1317.72 %*0.0977
=-128.80 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Nexalin Technology ROA % Related Terms

Thank you for viewing the detailed overview of Nexalin Technology's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Nexalin Technology (Nexalin Technology) Business Description

Traded in Other Exchanges
N/A
Address
1776 Yorktown, Suite 550, Houston, TX, USA, 77056
Nexalin Technology Inc design and develop innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy.
Executives
Marilyn Elson 10 percent owner, officer: Ms. Elson serves as CFO 32 CAMLET COURT, ROSELAND NJ 07068
Rick Morad director 6331 CHAGRIN RIVER ROAD, BENTLEYVILLE OH 44022
Mark White director, officer: President/CEO 1776 YORKTOWN STREET, SUITE 550, HOUSTON TX 77056
David Owens director, officer: Chief Medical Officer 4545 HARRIS TRAIL NW, ATLANTA GA 30327
Alan Kazden director 3435 CONSUELO DRIVE, CALABASAS CA 91302
Leonard Osser other: Spouse
Ben Hu director 7021 EDGERTON ROAD, NORTH ROYALTON OH 44133

Nexalin Technology (Nexalin Technology) Headlines

From GuruFocus

Nexalin Technology Provides 2022 Year-End Business Update

By sperokesalga sperokesalga 03-27-2023

Nexalin Technology CEO Provides Letter to Shareholders

By Stock market mentor Stock market mentor 01-05-2023